AxoGen, Inc. (NASDAQ:AXGN) is scheduled to be announcing its earnings results after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.
AxoGen (NASDAQ:AXGN) last issued its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The business had revenue of $15.20 million during the quarter, compared to analysts’ expectations of $14.40 million. During the same quarter in the previous year, the business earned ($0.09) EPS. The company’s revenue for the quarter was up 46.2% on a year-over-year basis. On average, analysts expect AxoGen to post $-0.34 EPS for the current fiscal year and $-0.12 EPS for the next fiscal year.
Shares of AxoGen, Inc. (AXGN) opened at 20.10 on Monday. The stock’s market cap is $668.12 million. The stock’s 50 day moving average price is $19.03 and its 200-day moving average price is $15.94. AxoGen, Inc. has a one year low of $7.65 and a one year high of $20.40.
In other news, Director Robert James Rudelius sold 16,143 shares of the stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $18.00, for a total transaction of $290,574.00. Following the transaction, the director now owns 43,273 shares of the company’s stock, valued at approximately $778,914. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 9.33% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/30/axogen-inc-axgn-to-release-quarterly-earnings-on-tuesday.html.
A number of equities research analysts have recently weighed in on the company. Leerink Swann reaffirmed an “outperform” rating and set a $23.00 price target (up from $22.00) on shares of AxoGen in a research note on Saturday, September 30th. Roth Capital reaffirmed a “buy” rating and set a $21.00 price target (up from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $18.00 price target on shares of AxoGen in a research note on Monday, August 21st. Finally, BidaskClub downgraded AxoGen from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. AxoGen has an average rating of “Buy” and an average target price of $17.40.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
What are top analysts saying about AxoGen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AxoGen Inc. and related companies.